Document Detail


Combined treatment with cytoprotective agents and radiotherapy.
MedLine Citation:
PMID:  20044209     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Radiotherapy is associated with several toxicities affecting healthy tissues. One of the strategies aimed at decreasing radiation toxicity is the use of radioprotective agents, such as amifostine and palifermin, or factors stimulating hemopoetic stem cells (colony stimulating factors, CSFs): granulocyte-CSF, granulocyte macrophage-CSF and recombinant erythropoetins. The potential beneficial effect of these substances demonstrated in preclinical in vitro and in vivo studies led to numerous clinical trials. This review addresses the current experience on the use of cytoprotective agents in combination with radiotherapy, with particular focus on the safety of these approaches. Despite a relatively large body of literature data, the role of cytoprotective agents combined with radiotherapy remains controversial. Overall, their use in this application is still limited due to modest radioprotective effect for normal tissues, potential risk of tumor protection and increased treatment toxicity. The use of erythropoetins in combination with radiotherapy should generally be discouraged, whereas the safe and effective application of other agents warrants further investigations.
Authors:
Piotr Winczura; Jacek Jassem
Related Documents :
2790149 - Aspergillus sinusitis in neutropenic patients with cancer: a review.
23483759 - Presence of differentiating neuroblasts in bone marrow is a favorable prognostic factor...
10501759 - Hematopoietic colony-stimulating factors for neutropenic patients in the icu.
20689429 - Leptomeningeal metastasis.
14558599 - Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposi...
22972569 - Can high-dose-rate brachytherapy prevent the major genitourinary complication better th...
2489239 - The role of reactive oxygen metabolites in the pathogenesis of ulcerative colitis: a sp...
23137549 - Clinical impact of ki-67 labeling index in non-small cell lung cancer.
2369729 - Photodynamic therapy by topical meso-tetraphenylporphinesulfonate tetrasodium salt admi...
Publication Detail:
Type:  Journal Article; Review     Date:  2009-12-30
Journal Detail:
Title:  Cancer treatment reviews     Volume:  36     ISSN:  1532-1967     ISO Abbreviation:  Cancer Treat. Rev.     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-04-12     Completed Date:  2010-05-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7502030     Medline TA:  Cancer Treat Rev     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  268-75     Citation Subset:  IM    
Copyright Information:
Copyright 2009 Elsevier Ltd. All rights reserved.
Affiliation:
Department of Oncology and Radiotherapy, Medical University of Gda?sk, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Combined Modality Therapy
Hematologic Neoplasms / drug therapy*,  radiotherapy*
Humans
Radiation-Protective Agents / therapeutic use*
Radiotherapy*
Chemical
Reg. No./Substance:
0/Radiation-Protective Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Demonstration of differences in virulence between two Theileria parva isolates.
Next Document:  Disgust affects TNF-alpha, IL-6 and noradrenalin levels in patients with obsessive-compulsive disord...